Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 9Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Glioblastoma 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Skin Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

enzalutamide 2radium Ra 223 dichloride 1poly ICLC 1olaparib 1fluciclovine F-18 1cabazitaxel 1bempegaldesleukin 1afuresertib 1Radiosurgery 1Radionuclide Imaging 1Prednisone 1Nivolumab 1Docetaxel 1Clinical Trials, Phase I as Topic 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-resistant Prostate Cancer × poly ICLC × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡